Ayaka Asakawa1, Hirotoshi Horio2, Takashi Yamamichi2, Masayuki Okui2, Masahiko Harada2. 1. Department of Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. aasakawa49@gmail.com. 2. Department of Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Abstract
OBJECTIVE: The purpose of this study was to clarify the surgical outcome for HIV-infected patients with non-small-cell lung cancer (NSCLC). METHODS: Six HIV-positive patients underwent lung resection as treatment for NSCLC at our hospital from July 2010 to December 2017. Their clinical information was collected based upon review of their medical records. RESULTS: All the patients included in this study had received highly active antiretroviral therapy (HAART) before lung resection with a mean duration of 99 months. Five patients underwent lobectomy and one patient underwent segmentectomy. Median preoperative CD4-positive T-cell count was 234/µL (range 138-428/µL). One patient contracted pneumonitis within 30 days post-surgery, whereas others had no postoperative complications. There was no postoperative mortality. For four patients, the pathological stage was upstaged compared to their clinical stage; IA1-IA3 (1 patient), IA3-IIB (1 patient), IB-IIIA (1 patient), and IB-IIIB (1 patient). Two patients died of lung cancer 2 years after surgery. CONCLUSION: Surgical treatment for HIV-infected patients with NSCLC receiving HAART therapy and keeping adequate CD4-positive T-cell counts is safe and feasible. Preoperative precise staging using diagnostic imaging is difficult for these patients.
OBJECTIVE: The purpose of this study was to clarify the surgical outcome for HIV-infectedpatients with non-small-cell lung cancer (NSCLC). METHODS: Six HIV-positive patients underwent lung resection as treatment for NSCLC at our hospital from July 2010 to December 2017. Their clinical information was collected based upon review of their medical records. RESULTS: All the patients included in this study had received highly active antiretroviral therapy (HAART) before lung resection with a mean duration of 99 months. Five patients underwent lobectomy and one patient underwent segmentectomy. Median preoperative CD4-positive T-cell count was 234/µL (range 138-428/µL). One patient contracted pneumonitis within 30 days post-surgery, whereas others had no postoperative complications. There was no postoperative mortality. For four patients, the pathological stage was upstaged compared to their clinical stage; IA1-IA3 (1 patient), IA3-IIB (1 patient), IB-IIIA (1 patient), and IB-IIIB (1 patient). Two patients died of lung cancer 2 years after surgery. CONCLUSION: Surgical treatment for HIV-infectedpatients with NSCLC receiving HAART therapy and keeping adequate CD4-positive T-cell counts is safe and feasible. Preoperative precise staging using diagnostic imaging is difficult for these patients.
Entities:
Keywords:
Highly active antiretroviral therapy (HAART); Human immunodeficiency virus (HIV); Non-small lung cancer
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Craig M Hooker; Robert A Meguid; Alicia Hulbert; Joshua T Taylor; James Shin; John Wrangle; Kristen Rodgers; Beverly Lee; Suvasini Laskshmanan; Travis Brown; Avedis Meneshian; Marc Sussman; Jeanne Keruly; Richard D Moore; Stephen C Yang; Malcolm V Brock Journal: Ann Thorac Surg Date: 2012-02 Impact factor: 4.330
Authors: U Tirelli; M Spina; S Sandri; D Serraino; C Gobitti; M Fasan; A Sinicco; P Garavelli; A L Ridolfo; E Vaccher Journal: Cancer Date: 2000-02-01 Impact factor: 6.860
Authors: Malcolm V Brock; Craig M Hooker; Eric A Engels; Richard D Moore; Maura L Gillison; Anthony J Alberg; Jeanne C Keruly; Stephen C Yang; Richard F Heitmiller; Stephen B Baylin; James G Herman; Julie R Brahmer Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Michael J Silverberg; Chun Chao; Wendy A Leyden; Lanfang Xu; Michael A Horberg; Daniel Klein; William J Towner; Robert Dubrow; Charles P Quesenberry; Romain S Neugebauer; Donald I Abrams Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-22 Impact factor: 4.254
Authors: Nancy A Hessol; Otoniel Martínez-Maza; Alexandra M Levine; Alison Morris; Joseph B Margolick; Mardge H Cohen; Lisa P Jacobson; Eric C Seaberg Journal: AIDS Date: 2015-06-19 Impact factor: 4.177
Authors: Gabriela A D'Jaen; Liron Pantanowitz; Mark Bower; Susan Buskin; Nancy Neil; Erin M Greco; Timothy P Cooley; David Henry; Jonathan Stem; Bruce J Dezube; Justin Stebbing; David M Aboulafia Journal: Clin Lung Cancer Date: 2010-11-01 Impact factor: 4.785
Authors: Eric A Engels; Malcolm V Brock; Jinbo Chen; Craig M Hooker; Maura Gillison; Richard D Moore Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391